Nox Health’s mission is to transform lives through the power of sleep, using a combination of data, science, technology, and empathetic care. In 2023, Nox acquired Somryst, the first-ever FDA-approved digital therapeutic for chronic insomnia. Somryst delivers Cognitive Behavioral Therapy for Insomnia (CBT-I) and has been shown to improve sleep quality in over 52 randomized controlled trials and real-world studies. In addition to Somryst, Nox provides at-home testing for sleep apnea and value-based sleep care to meet the needs of over 8,000 members at 32 different companies and counting. Nox also develops cutting-edge sleep diagnostics to help millions of people around the world, as well as serving local residents through a brick-and-mortar sleep clinic in Alpharetta, GA.